Showing posts with label journal of cardiovascular disease. Show all posts
Showing posts with label journal of cardiovascular disease. Show all posts

Tuesday, 16 May 2017

Therapeutic Potential of Adenosine Transport Modulators for Cardiovascular Protection

Cardiovascular disease including stroke is the leading cause of death and disability worldwide and an enormous economic burden to our societies. Based on the latest statistics released for heart and stroke disease, an estimated 83,600,000 adults in the United State (US) (>30%) have one or more types of cardiovascular disease (CVD) of whom more than 90% have hypertension, 18% have coronary heart disease (CHD), close to 10% have myocardial infarction (MI) and 8% have stroke. 

adenosine receptors

The total direct and indirect cost in the US alone for treatment of cardiovascular diseases (hospitalization, drugs, home healthcare, etc.) and loss of productivity and morbidity is estimated at close to $315 billion US per year. Thus prevention by improving diagnosis and drug treatment strategies could provide a huge saving for the health care cost worldwide. Read more>>>>>>>>

Monday, 8 May 2017

Importance of Gender Effect in Cardiovascular Pharmacology

Cardiovascular Disease (CVD) including stroke is the leading cause of death and disability worldwide and an enormous economic burden to our societies. The total direct and indirect cost in the US alone for treatment of CVD (hospitalization, drugs, home healthcare, etc.) and loss ofproductivity and morbidity is estimated at close to $315 billion US per year. 

Cardiovascular Pharmacology

Thus prevention by improving diagnosis and drug treatment strategies could provide a huge saving for the health care cost worldwide. The importance of gender effect in the management of CVD has long been recognized such that mortality and morbidity are higher in women than men. Compared to men, women tend to develop significant CVD later in life, but their prognosis are considerably poorer and it is now the leading cause of death in elderly women. Read more>>>>>>>>>

Tuesday, 2 May 2017

Are Endothelial Cell-Derived Microparticles Predictive Biomarkers in Cardiovascular Diseases?

Endothelial-derived microparticles (MPs) are defined as heterogeneous population of plasma membrane vesicles (diameter 100-1000 nm) produced by apoptotic or activated cells originated from vascular endothelium or circulating endothelial cell. 

Cell-Derived Microparticles

They are derived from cell membrane surfaces via blebbing and shedding in physiological (stress, micro environmental stimulation) and pathological (coagulation/thrombosis, endotoxinemia, endothelial shear stress, ischemic/hypoxic injury, inflammation, and malignancy) conditions and are present in low concentrations in normal plasma. Recent investigations have been shown that endothelial-derived MPs are discussed powerful paracrine regulators of target cell functions affected cell differentiation, tissue growth and reparation, vasculogenesis, vasodilation, inflammation, apoptosis, infection, and malignancy.Read more>>>>>>>>>>

Monday, 10 April 2017

Summative Evaluation of Physician-Pharmacist Collaboration Management

As the health care system adapts to the growing population living with chronic disease there has been a shift in the delivery of primary care towards a team-based, patient-centered model. The benefits of including a pharmacist as amember of a collaborative medical team have been well established. Several systematic reviews and meta analyses have shown the positive impact pharmacists have on improving BP control and managing other cardiovascular risk factors.

Physician-Pharmacist Collaboration Management

The American College of Clinical Pharmacy (ACCP) Ambulatory Care Practice and Research Network (PRN) recently published a paper stressing the importance of pharmacists in the optimization of medication management in the Patient Centered Medical Home (PCMH) and identify pharmacists as an essential component to the success of the PCMH model.  Read more>>>>>>>>>

Thursday, 12 January 2017

Treatment of Severe Aortic Stenosis



Severe valvular aortic stenosis (AS) is an aortic valve area of less than 1.0 cm2. Anginapectoris, syncope or near syncope, and congestive heart failure (CHF) are the 3 classic manifestations of severe AS. 

 
Patients with symptomatic severe valvular AS have a poor prognosis. Ross and Braunwald found that the average survival rate was 3 years after the onset of angina pectoris in patients with severe AS. Ross and Braunwald reported that the average survival rate after the onset of syncope in patients with severe AS was 3 years. Ross and Braunwald showed that the average survival rate after the onset of CHF in patients with severe AS was 1.5 to 2 years.  Read more>>>>>>>>>>>>>http://www.esciencecentral.org/journals/treatment-of-severe-aortic-stenosis-2329-9517.1000e101.php?aid=10906

Friday, 25 November 2016

Glycosaminoglycans (GAGs) in Cardiovascular Disease: Searching for the Sweet Spot

One of the seminal discoveries in biology was the discovery of the structure of deoxyribonucleic acid, DNA, by James Watson, Francis Crick and Rosalind Franklin that led to the later deciphering of the genetic code by a series of exceptional researchers. Without Rosalind Franklin’s X ray crystallography work on the hydrated form of DNA, Watson and Crick would not have been able to decipher the double helix. It is this underlying structure that allows DNA to direct the transcription of RNA and later translation of the genetic code into proteins. In simple terms without understanding the structure, the geneticfunction of DNA was not evident. 

Glycosaminoglycans
While the genetic code directs all protein synthesis, it is also true that in many instances understanding what genes are expressed and translated does not inform the actual final functions, the end result of protein expression and activity.The mere presence of a protein or enzyme also does not translate directly into an outcome in activity. Function is a much more complex process. Thus the genetic code can direct amino acid sequence and structure, but structure and location can also modify ultimate function. With this editorial we discuss the effects of one structural component, the glycosaminoglycans (GAGs), on the functional activities of other molecules, cells and organs. GAGs represent one of the silent engineers of cellular and tissue structures.  Read more.................

Wednesday, 2 November 2016

FGF10 Signaling Enhances Epicardial Cell Expansion during Neonatal Mouse Heart Repair

In contrast to newt and zebrafish, adult mammalian hearts have a very limited capacity to regenerate. Ischemia in the mammalian heart causes significant tissue damage with the loss of many cardiac cells through apoptosis and necrosis, only to be replaced with nonfunctional fibrotic tissue and hypertrophy but not hyperplasia of the remaining cardiomyocytes. After an ischemic episode, the heart is permanently scarred and functionally impaired, leading to lifelong morbidity or ultimately death. 

Neonatal Mouse Heart Repair


Cardiovascular disease affects millions of people in the USA and is the leading cause of all mortality. Determining the precise mechanisms and initiators for regeneration may lead to possible therapeutic agents for human patients, decreasing mortality and morbidity from ischemic heart diseases. Recently, neonatal mouse hearts were shown to regenerate after ventricular resection in a similar fashion to adult zebrafish. Furthermore, it was demonstrated they can also regenerate after ischemia created by coronary artery ligation. Read more..............

Tuesday, 1 November 2016

Treatment of Severe Aortic Stenosis

Severe valvular aortic stenosis (AS) is an aortic valve area of less than 1.0 cm2. Angina pectoris, syncope or near syncope, and congestive heart failure (CHF) are the 3 classic manifestations of severe AS. Patients with symptomatic severe valvular AS have a poor prognosis. Ross and Braunwald found that the average survival rate was 3 years after the onset of angina pectoris in patients with severe AS. Ross and Braunwald reported that the average survival rate after the onset of syncope in patients with severe AS was 3 years. 

Severe Aortic Stenosis


Ross and Braunwald showed that the average survival rate after the onset of CHF in patients with severe AS was 1.5 to 2 years. In a prospective study, at 19-month follow-up (range 2 to 36 months), 90% of 30 patients with CHF associated with unoperated severe AS and a normal left ventricular ejection fraction (LVEF) were dead. At 13-month follow-up (range 2 to 24 months), 100% of 18 patients with CHF associated with unoperated severe AS and an abnormal LVEF were dead. Read more..............